http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2828985-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8381805eba6d034fc77bd230dd02e6e2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-974 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54306 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2014-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_318401b27394ea16f274e78c35d149be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b57ab54916822ff9249c0bf3998bd182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_496d5b54c23e1c26fda2ab1c2f36c753 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0befacba1979901a89542dd3c690f565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ea59ac52beb1b32eb494ac9a70183b |
| publicationDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2828985-T3 |
| titleOfInvention | Affinity-based detection of synthetic ligand-encoded biomarkers |
| abstract | A method, comprising: collecting a urine sample from a subject, suspected of having a disorder or condition, wherein the subject has been administered a biomarker nanoparticle, wherein the biomarker nanoparticle comprises a modular structure, having a carrier domain bound to a detectable enzyme-susceptible marker, wherein the detectable enzyme-susceptible label comprises an enzyme-susceptible domain bound to a detectable label whereby the detectable label is released from the biomarker nanoparticle when exposed to a protease, wherein the detectable label comprises a capture ligand and a detection ligand, linked by glutamate-fibrinopeptide B (GluFib) [SEQ ID NO: 1], and wherein the capture ligand is selected from the group consisting in fluorescein, dinitrophenyl, tetra-methylrhodamine and Alexa Fluor 488 and the detection ligand is biotin; and subjecting the urine sample to a method of analysis by a capture assay, wherein the capture assay involves an affinity step, binding an affinity agent to the capture ligand and to a detection step, detecting the detection ligand for detecting the presence of the ligand marker, and the presence of the ligand marker in the biological sample being indicative of the disorder or condition within the subject. |
| priorityDate | 2013-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 739.